The treatment policy estimand evaluated the treatment effect among all participants, regardless of treatment discontinuation or rescue intervention, while the trial product estimand addressed the average treatment effect in all participants assuming adherence to the treatment protocol
Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion
Days 2 to 3: Peak plasma levels
A realistic UK approval window is late 2027 to mid 2028, with NHS availability through NICE technology appraisal arriving in 2029 at the earliest
Here we report beneficial effects of treatment with liraglutide, a glucagon-like peptide-1 (GLP-1) analog, on severe obsessive food craving, binge eating, weight gain, and behavioral problems in an adolescent male with infantile autism and moderate intellectual impairment